Who the Tymlos label covers
Abaloparatide is modeled on part of a peptide related to parathyroid hormone. The U.S. Tymlos pen contains 3,120 mcg in 1.56 mL, with 30 labeled doses of 80 mcg.
The label covers treatment of postmenopausal women with osteoporosis and use to increase bone density in men with osteoporosis. In each case, it applies to people at high fracture risk or people for whom other available osteoporosis therapy failed or was intolerable.
Sources for this section
Fracture and bone-density results answer different questions
In the 18-month ACTIVE trial in postmenopausal women with osteoporosis, new spine fractures on X-ray occurred in about 0.6% of participants receiving abaloparatide and 4.2% of those receiving placebo. The trial also found fewer fractures outside the spine with abaloparatide than with placebo.
In the 12-month ATOM trial in men with osteoporosis, spine bone mineral density rose by about 8.5% with abaloparatide and 1.2% with placebo. That trial assessed bone density, a measure of how much mineral is in bone. It does not quantify how many fractures the medicine prevents in men.
Sources for this section
What to discuss before starting
Ask how the clinician will follow bone health and reassess the treatment plan. The Tymlos label discourages more than two lifetime years of use because safety and effectiveness beyond that duration have not been evaluated.
The label warns about serious allergic reactions and high blood or urine calcium. It also advises avoiding the medicine in people at increased risk of osteosarcoma, including some people with prior radiation involving the skeleton or a history of bone cancer. A clinician can review the medical factors relevant to the choice.